| DESCRIPTION | - AGGARWAL ET AL., JBC, (1985), vol. 260, page 2345 | - |
| DESCRIPTION | - AGNEW, CHEM INTL. ED. ENGL., (1994), vol. 33, pages 183 - 186 | - |
| DESCRIPTION | - ALBERT ET AL., "A Phase I Trial of Rituximab (Anti-CD20) for Treatment of Systemic Lupus Erythematosus", ARTHRITIS AND RHEUMATISM, (200312), vol. 48, no. 12, pages 3659 - 3659 | - |
| DESCRIPTION | - A. L. LEHNINGER, Biochemistry, WORTH PUBLISHERS, (1975), pages 73 - 75 | - |
| DESCRIPTION | - ANDERSON ET AL., ANN NEUROLOGY, (1992), vol. 31, no. 3, pages 333 - 336 | - |
| DESCRIPTION | - ANDERSON ET AL., BLOOD, (1984), vol. 63, no. 6, pages 1424 - 1433 | - |
| DESCRIPTION | - ANDERSON ET AL., SCIENCE, (1992), vol. 256, pages 808 - 813 | - |
| DESCRIPTION | - ANDERSSON ET AL., EUR J NEUROL, (2002), vol. 9, pages 243 - 251 | - |
| DESCRIPTION | - ANOLIK ET AL., "B lympocyte Depletion in the Treatment of Systemic Lupus (SLE): Phase I/II Trial of Rituximab (RITUXAN@) in SLE", ARTHRITIS AND RHEUMATISM, (200210), vol. 46, no. 9, pages S289 - S289 | - |
| DESCRIPTION | - BAR-OR A., "Safety, pharmacodynamics, and activity of Rituximab in patients with relapsing-remitting multiple sclerosis: a phase I, multicentre, open-label clinical trial", ANN NEUROL, (2008), vol. 63, no. 3, pages 395 - 400 | - |
| DESCRIPTION | - BERGER ET AL., N ENGL J MED, (2003), vol. 349, pages 139 - 145 | - |
| DESCRIPTION | - BIELEKOVA ET AL., NAT MED, (2000), vol. 6, pages 1167 - 1175 | - |
| DESCRIPTION | - BRENNAN ET AL., SCIENCE, (1985), vol. 229, page 81 | - |
| DESCRIPTION | - BRODEUR ET AL., Monoclonal Antibody Production Techniques and Applications, MARCE DEKKER, INC., (1987), pages 51 - 63 | - |
| DESCRIPTION | - BRUGGERMANN ET AL., YEAR IN IMMUNO., (1993), vol. 7, page 33 | - |
| DESCRIPTION | - CAPEL ET AL., IMMUNOMETHODS, (1994), vol. 4, pages 25 - 34 | - |
| DESCRIPTION | - CARON ET AL., J. EXP MED., (1992), vol. 176, pages 1191 - 1195 | - |
| DESCRIPTION | - CARTER ET AL., BIO/TECHNOLOGY, (1992), vol. 10, pages 163 - 167 | - |
| DESCRIPTION | - CARTER ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, page 4285 | - |
| DESCRIPTION | - CEPOK, BRAIN, (2001), vol. 124, pages 2169 - 2176 | - |
| DESCRIPTION | - CHARI ET AL., CANCER RESEARCH, (1992), vol. 52, pages 127 - 131 | - |
| DESCRIPTION | - CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, page 901 | - |
| DESCRIPTION | - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917 | - |
| DESCRIPTION | - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628 | - |
| DESCRIPTION | - CLARK ET AL., PROC. NATL. ACAD. SCI. (USA, (1985), vol. 82, page 1766 | - |
| DESCRIPTION | - CLYNES ET AL., PNAS (USA), (1998), vol. 95, pages 652 - 656 | - |
| DESCRIPTION | - CONFAVREUX ET AL., N ENGL JMED, (2000), vol. 343, no. 20, pages 1430 - 1438 | - |
| DESCRIPTION | - CRAGG ET AL., BLOOD, (2003), vol. 101, pages 1045 - 1052 | - |
| DESCRIPTION | - CREE ET AL., "An open label study of the effects of rituximab in neuromyelitis optica", NEUROLOGY, (2005), vol. 64, no. 7, pages 1270 - 1272, XP009071970 | - |
| DESCRIPTION | - CREE ET AL., NEUROLOGY, (2005), vol. 64, pages 1270 - 1272 | - |
| DESCRIPTION | - CROSS ET AL., EIGHTH ANNUAL MEETING OF THE AMERICAS COMMITTEES FOR RESEARCH AND TREATMENT IN MULTIPLE SCLEROSIS, (2003), pages 20 - 21 | - |
| DESCRIPTION | - CROSS ET AL., J. NEUROIMMUNOL., (2006), vol. 180, pages 63 - 70 | - |
| DESCRIPTION | - CROSS ET AL., "Preliminary results from a phase II trial of Rituximab", MS (ABSTRACT) EIGHTH ANNUAL MEETING OF THE AMERICAS COMMITTEES FOR RESEARCH AND TREATMENT IN MULTIPLE SCLEROSIS, (2003), pages 20 - 21 | - |
| DESCRIPTION | - CUNNINGHAM; WELLS, SCIENCE, (1989), vol. 244, pages 1081 - 1085 | - |
| DESCRIPTION | - DAERON, ANNU. REV. IMMUNOL., (1997), vol. 15, pages 203 - 234 | - |
| DESCRIPTION | - D'ARENA ET AL., LEUK LYMPHOMA, (2003), vol. 44, pages 561 - 562 | - |
| DESCRIPTION | - DE HAAS ET AL., J. LAB. CLIN. MED., (1995), vol. 126, pages 330 - 341 | - |
| DESCRIPTION | - DEMIDEM ET AL., CANCER CHEMOTHERAPY & RADIOPHARMACEUTICALS, (1997), vol. 12, no. 3, pages 177 - 186 | - |
| DESCRIPTION | - DEVITA ET AL., "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis", ARTHRITIS & RHEUM, (2002), vol. 46, pages 2029 - 2033 | - |
| DESCRIPTION | - DORAN ET AL., ARTHRITIS RHEUM, (2002), vol. 46, pages 2287 - 2293 | - |
| DESCRIPTION | - EDWARDS ET AL., BIOCHEM SOC TRANS, (2002), vol. 30, pages 824 - 828 | - |
| DESCRIPTION | - EDWARDS ET AL., "Efficacy and safety of Rituximab, a B-cell targeted chimeric monoclonal antibody: A randomized, placebo controlled trial in patients with rheumatoid arthritis", ARTHRITIS AND RHEUMATISM, (2002), vol. 46, no. 9, page 197 | - |
| DESCRIPTION | - EGG ET AL., MULT SCLER, (2001), vol. 7, no. 5, pages 285 - 289 | - |
| DESCRIPTION | - EINFELD ET AL., EMBO J., (1988), vol. 7, no. 3, pages 711 - 717 | - |
| DESCRIPTION | - EISENBERG R., ARTHRITIS RES THER, (2003), vol. 5, pages 157 - 159 | - |
| DESCRIPTION | - EMERY ET AL., ARTHRITIS RHEUM, (2003), vol. 48, no. 9, page S439 | - |
| DESCRIPTION | - EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, page 3688 | - |
| DESCRIPTION | - ESIRI M., NEUROPATHOL APPL NEUROBIOL, (1980), vol. 6, pages 9 - 21 | - |
| DESCRIPTION | - FILIPPINI ET AL., LANCET, (2003), vol. 361, pages 545 - 552 | - |
| DESCRIPTION | - GABIZON ET AL., J. NATIONAL CANCER INST., (1989), vol. 81, no. 19, page 1484 | - |
| DESCRIPTION | - GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, (1996), vol. 202, page 163 | - |
| DESCRIPTION | - GENAIN ET AL., NAT MED, (1999), vol. 5, pages 170 - 175 | - |
| DESCRIPTION | - GLENNIE; VAN DE WINKEL, DRUG DISCOVERY TODAY, (2003), vol. 8, pages 503 - 510 | - |
| DESCRIPTION | - GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103 | - |
| DESCRIPTION | - GRIFFITH ET AL., EMBO J., (1993), vol. 12, pages 725 - 734 | - |
| DESCRIPTION | - GRUBER ET AL., J. IMMUNOL., (1994), vol. 152, page 5368 | - |
| DESCRIPTION | - GUYER ET AL., J. IMMUNOL., (1976), vol. 117, page 587 | - |
| DESCRIPTION | - HAEMATOLOGICA, (2002), vol. 87, page 336 | - |
| DESCRIPTION | - HAINSWORTH ET AL., J CLIN ONCOL, (2002), vol. 20, pages 4261 - 4267 | - |
| DESCRIPTION | - HAINSWORTH ET AL., J CLIN ONCOL, (2003), vol. 21, pages 1746 - 1751 | - |
| DESCRIPTION | - HAWKER K, "Efficacy and Safety of rituximab in patients with primary progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, multicenter trial", NEUROLOGY, (2009), vol. 72, no. S3, page A254 | - |
| DESCRIPTION | - HAWKER K ET AL., "Efficacy and Safety of rituximab in patients with primary progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, multicenter trial", MULTIPLE SCLEROSIS, (2008), vol. 14, no. 1, page S299, XP009128819 | - |
| DESCRIPTION | - HINMAN ET AL., CANCER RESEARCH, (1993), vol. 53, pages 3336 - 3342 | - |
| DESCRIPTION | - HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448 | - |
| DESCRIPTION | - HWANG ET AL., PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, page 4030 | - |
| DESCRIPTION | - INGLE ET AL., BRAIN, (2003), vol. 126, pages 2528 - 2536 | - |
| DESCRIPTION | - INGLE ET AL., J. NEUROL NEUROSURG PSYCHIATRY, (2005), vol. 76, no. 9, pages 1255 - 1258 | - |
| DESCRIPTION | - IZQUIERDO ET AL., ACTA NEUROL SCAND, (2002), vol. 105, pages 158 - 163 | - |
| DESCRIPTION | - JAKOBOVITS ET AL., NATURE, (1993), vol. 362, pages 255 - 258 | - |
| DESCRIPTION | - JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, page 2551 | - |
| DESCRIPTION | - JOHNSON, KEVIN S.; CHISWELL, DAVID J., CURRENT OPINION IN STRUCTURAL BIOLOGY, (1993), vol. 3, pages 564 - 571 | - |
| DESCRIPTION | - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525 | - |
| DESCRIPTION | - KIM ET AL., J. IMMUNOL., (1994), vol. 24, page 249 | - |
| DESCRIPTION | - KOHLER ET AL., NATURE, (1975), vol. 256, page 495 | - |
| DESCRIPTION | - KOSTELNY ET AL., J. IMMUNOL., (1992), vol. 148, no. 5, pages 1547 - 1553 | - |
| DESCRIPTION | - KOZBOR, J. IMMUNOL., (1984), vol. 133, page 3001 | - |
| DESCRIPTION | - KREMENCHUTZKY ET AL., BRAIN, (1999), vol. 122, pages 1941 - 1950 | - |
| DESCRIPTION | - KREMENCHUTZKY ET AL., BRAIN, (2006), vol. 129, pages 584 - 594 | - |
| DESCRIPTION | - KURTZKE, J. NEUROLOGY, (1983), vol. 33, no. 11, pages 1444 - 1152 | - |
| DESCRIPTION | - LANEWAY, NATURE, (1989), vol. 341, page 482 | - |
| DESCRIPTION | - LEANDRO ET AL., ANN RHEUM DIS., (2002), vol. 61, pages 883 - 888 | - |
| DESCRIPTION | - LEANDRO ET AL., ARTHRITIS RHEUM, (2002), vol. 46, pages 2673 - 2677 | - |
| DESCRIPTION | - LEANDRO ET AL., "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion", ANN RHEUM DIS, (2002), vol. 61, pages 833 - 888 | - |
| DESCRIPTION | - LEANDRO ET AL., "Lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response", ARTHRITIS AND RHEUMATISM, (2001), vol. 44, no. 9, page 370 | - |
| DESCRIPTION | - LEVINE; PESTRONK, "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab", NEUROLOGY, (1999), vol. 52, pages 1701 - 1704, XP000942610 | - |
| DESCRIPTION | - LODE ET AL., CANCER RESEARCH, (1998), vol. 58, pages 2925 - 2928 | - |
| DESCRIPTION | - LUCCHINETTI ET AL., ANN NEUROL, (2000), vol. 47, pages 707 - 717 | - |
| DESCRIPTION | - MALONEY ET AL., BLOOD, (1996), vol. 88, no. 10, page 637A | - |
| DESCRIPTION | - MARKS ET AL., BIOLTECHNOLOGY, (1992), vol. 10, pages 779 - 783 | - |
| DESCRIPTION | - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597 | - |
| DESCRIPTION | - MARTIN ET AL., J. BIOL. CHEM., (1982), vol. 257, pages 286 - 288 | - |
| DESCRIPTION | - MASSEY, NATURE, (1987), vol. 328, pages 457 - 458 | - |
| DESCRIPTION | - MATA ET AL., MULT SCLER, (1999), vol. 5, pages 379 - 388 | - |
| DESCRIPTION | - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 553 | - |
| DESCRIPTION | - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 554 | - |
| DESCRIPTION | - MCDONALD ET AL., ANN NEUROL, (2001), vol. 50, pages 121 - 127 | - |
| DESCRIPTION | - MILLSTEIN ET AL., NATURE, (1983), vol. 305, pages 537 - 539 | - |
| DESCRIPTION | - MORIMOTO, JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, (1992), vol. 24, pages 107 - 117 | - |
| DESCRIPTION | - MORRISON ET AL., PROC. NATL ACAD. SCI. USA, (1984), vol. 81, page 6851 | - |
| DESCRIPTION | - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855 | - |
| DESCRIPTION | - MUNSON ET AL., ANAL. BIOCHEM., (1980), vol. 107, page 220 | - |
| DESCRIPTION | - NAT MED, (2000), vol. 6, page 1412 | - |
| DESCRIPTION | - NEUBERGER ET AL., NATURE, (1984), vol. 312, pages 604 - 608 | - |
| DESCRIPTION | - NEUROLOGY, (1999), vol. 53, pages 457 - 465 | - |
| DESCRIPTION | - NOONAN ET AL., NEUROLOGY, (2002), vol. 58, pages 136 - 138 | - |
| DESCRIPTION | - O'CONNOR, P., NEUROLOGY, (2002), vol. 59, pages S1 - S33 | - |
| DESCRIPTION | - OFFNER ET AL., SCIENCE, (1991), vol. 251, pages 430 - 432 | - |
| DESCRIPTION | - OKAZAKI ET AL., J. MOL. BIOL., (2004), vol. 336, pages 1239 - 1249 | - |
| DESCRIPTION | - PENNICA ET AL., NATURE, (1984), vol. 312, page 721 | - |
| DESCRIPTION | - PEROTTA; ABUEL, "Response of chronic relapsing ITP of 10 years duration to Rituximab", BLOOD, (1998), vol. 10, no. L, page 88B | - |
| DESCRIPTION | - PESTRONK ET AL., J NEUROL NEUROSURG PSYCHIATRY, (2003), vol. 74, pages 485 - 489 | - |
| DESCRIPTION | - PLUCKTHUN, LMMUNOL. REVS., (1992), vol. 130, pages 151 - 188 | - |
| DESCRIPTION | - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315 | - |
| DESCRIPTION | - PRANZATELLI ET AL., NEUROLOGY, (2003), vol. 60, no. LL | - |
| DESCRIPTION | - PRESS ET AL., BLOOD, (1987), vol. 69, no. 2, pages 584 - 591 | - |
| DESCRIPTION | - PRESTA, CURR. OP. STRUCT. BIOL, (1992), vol. 2, pages 593 - 596 | - |
| DESCRIPTION | - PRESTA ET AL., J. IMMUNOL., (1993), vol. 151, page 2623 | - |
| DESCRIPTION | - PRINEAS; WRIGHT, LAB INVEST, (1978), vol. 38, pages 409 - 421 | - |
| DESCRIPTION | - RAVETCH; KINET, ANNU. REV. IMMUNOL, (1991), vol. 9, pages 457 - 492 | - |
| DESCRIPTION | - REFF ET AL., BLOOD, (1994), vol. 83, no. 2, pages 435 - 445 | - |
| DESCRIPTION | - REINDL ET AL., BRAIN, (1999), vol. 122, pages 2047 - 2056 | - |
| DESCRIPTION | - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327 | - |
| DESCRIPTION | - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329 | - |
| DESCRIPTION | - RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., (1986), vol. 249, pages 533 - 545 | - |
| DESCRIPTION | - ROXBURGH ET AL., NEUROLOGY, (2005), vol. 64, pages 1144 - 1151 | - |
| DESCRIPTION | - RUDICK ET AL., MULT SCLER, (1995), vol. 1, pages 150 - 155 | - |
| DESCRIPTION | - SADATIPOUR ET AL., ANN NEUROL, (1998), vol. 44, pages 980 - 983 | - |
| DESCRIPTION | - SASTRE-GARRIGA ET AL., NEUROLOGY, (2005), vol. 65, no. 4, pages 633 - 635 | - |
| DESCRIPTION | - SHOPES, B. J., LMMUNOL., (1992), vol. 148, pages 2918 - 2922 | - |
| DESCRIPTION | - SIDEN A., J NEUROL, (1979), vol. 221, pages 39 - 51 | - |
| DESCRIPTION | - SIMS ET AL., J. IMLNUNOL., (1993), vol. 151, page 2296 | - |
| DESCRIPTION | - SKERRA ET AL., CURR. OPINION IN IMMUNOL., (1993), vol. 5, pages 256 - 262 | - |
| DESCRIPTION | - STASHI ET AL., "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idopathic thrombocytopenic purpura", BLOOD, (2001), vol. 98, no. 4, pages 952 - 957 | - |
| DESCRIPTION | - STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, (1989), vol. 3, pages 219 - 230 | - |
| DESCRIPTION | - STUVE ET AL., NEUROLOGY, (2002), vol. 8, pages 290 - 301 | - |
| DESCRIPTION | - SURESH ET AL., METHODS IN ENZYMOLOGY, (1986), vol. 121, page 210 | - |
| DESCRIPTION | - SZCZEPANSKI ET AL., ARTHRITIS RHEUM, (2003), vol. 48, no. 9, page 121 | - |
| DESCRIPTION | - TEDDER ET AL., J. CELL. BIOCHEM., (1990), vol. 14D, page 195 | - |
| DESCRIPTION | - TEDDER ET AL., J. IMMUNOL., (1985), vol. 135, no. 2, pages 973 - 979 | - |
| DESCRIPTION | - TRAUNECKER ET AL., EMBO J., (1991), vol. 10, pages 3655 - 3659 | - |
| DESCRIPTION | - TREMLETT ET AL., MULT SCLER., (2008), vol. 14, no. 3, pages 314 - 324 | - |
| DESCRIPTION | - TREMLETT ET AL., NEUROLOGY, (2005), vol. 65, no. 12, pages 1919 - 1923 | - |
| DESCRIPTION | - TUTT, J. IMMUNOL., (1991), vol. 147, page 60 | - |
| DESCRIPTION | - VALENTINE ET AL., J. BIOL. CHEM., (1989), vol. 264, no. 19, pages 11282 - 11287 | - |
| DESCRIPTION | - VALENTINE ET AL., Leukocyte Typing III, OXFORD UNIVERSITY PRESS, (1987), page 440 | - |
| DESCRIPTION | - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536 | - |
| DESCRIPTION | - VILLAR ET AL., ANN NEUROL, (2003), vol. 53, pages 222 - 226 | - |
| DESCRIPTION | - VITETTA ET AL., SCIENCE, (1987), vol. 238, page 1098 | - |
| DESCRIPTION | - WAGNER ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 3410 - 3414 | - |
| DESCRIPTION | - WATERHOUSE ET AL., NUC. ACIDS. RES., (1993), vol. 21, pages 2265 - 2266 | - |
| DESCRIPTION | - WEINSHENKER ET AL., BRAIN, (1989), vol. 112, pages 133 - 146 | - |
| DESCRIPTION | - WINGERCHUK ET AL., LAB INVEST, (2001), vol. 81, pages 263 - 281 | - |
| DESCRIPTION | - WOLFF ET AL., CANCER RESEARCH, (1993), vol. 53, pages 2560 - 2565 | - |
| DESCRIPTION | - WOLINSKY J., JNEUROL SCI, (2003), vol. 206, pages 145 - 152 | - |
| DESCRIPTION | - WU ET AL., J. BIOL. CHEM., (1987), vol. 262, pages 4429 - 4432 | - |
| DESCRIPTION | - YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., (2004), vol. 87, page 614 | - |
| DESCRIPTION | - ZAJA ET AL., HAEMATOLOGICA, (2002), vol. 87, pages 189 - 195 | - |
| DESCRIPTION | - ZEMAN ET AL., ACTA CYTOL, (2001), vol. 45, pages 51 - 59 | - |
| DESCRIPTION | - SPECKS ET AL., "Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy", ARTHRITIS & RHEUMATISM, (2001), vol. 44, no. 12, doi:doi:10.1002/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W, pages 2836 - 2840, XP002406917 | |
| DESCRIPTION | - LEANDRO ET AL., "An open study of B lymphocyte depletion in systemic lupus erythematosus", ARTHRITIS & RHEUMATISM, (2002), vol. 46, no. 1, doi:doi:10.1002/art.10541, pages 2673 - 2677, XP002378313 | |
| DESCRIPTION | - CROSS ET AL., "Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients", J NEUROIMMUNOL, (2006), vol. 180, no. 1-2, doi:doi:10.1016/j.jneuroim.2006.06.029, pages 63 - 70, XP025039481 | |
| DESCRIPTION | - MARTIN; CHAN, "Pathogenic Roles of B cells in Human Autoimmunity: Insights from the Clinic", IMMUNITY, (2004), vol. 20, doi:doi:10.1016/S1074-7613(04)00112-8, pages 517 - 527, XP002456838 | |
| DESCRIPTION | - EDWARDS ET AL., "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders", BIOCHEM. SOC. TRANS., (2002), vol. 30, no. 4, doi:doi:10.1042/BST0300824, pages 824 - 828, XP002306250 | |
| DESCRIPTION | - HAUSER S. ET AL., "B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis", NEJM, (2008), vol. 358, no. 7, doi:doi:10.1056/NEJMoa0706383, pages 676 - 688, XP002567454 | |
| DESCRIPTION | - EDWARDS; CAMBRIDGE, "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes", RHEMATOLOGY, (2001), vol. 40, doi:doi:10.1093/rheumatology/40.2.205, pages 205 - 211, XP002348931 | |
| OPPOSITION | - Anonymous, "Ocrelizumab in patients with Relapsing-Remitting Multiple Sclerosis (RRMS)", Phoenix Neurological Associates, (2008), pages 1 - 1, XP055821059 | - |
| OPPOSITION | - Anonymous, "RITUXAN (Rituximab)", US BL 103705 Supplement Amendment: Rituxan Rheumatoid Arthritis, (20060200), pages 1 - 53, XP055820997 | - |
| OPPOSITION | - Anonymous, "Trial Information, Summary: A Dose-Finding Study of Oc- relizumab in Patients with Relapsing-Remitting Multiple Sclerosis", CENTERWATCH Clinical Trial Information Service, (20080829), pages 1 - 2, XP055821052 | - |
| OPPOSITION | - Confirmation of publication date of D5- 29 August 2008 (2008-08-29) | - |
| OPPOSITION | - E. WAUBANT, "Sclerose en plaques", Rev. Neurol., (20070000), vol. 163, no. 6-7, pages 688 - 696, XP055821012 | - |
| OPPOSITION | - GENOVESE et al., "Ocrelizumab, a humanized antbCOiO monodonai antibody, in the treatment of patients with rheumatoid arthritis: A phase l/l I randomized, blinded, placebo-controlled,, dose-ranging study", Arthritis & Rheumatism, (20080000), vol. 58, no. 9, pages 2652 - 2661, XP055817631 | - |
| OPPOSITION | - ROCHE TRIAL INFORMATION, "A Dose-Finding Study of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis", Clinical Trial Search, (20080828), pages 1 - 5, XP055821000 | - |
| OPPOSITION | - WAYBACK MACHINE- Confirmation of publication date of BHF2, 28 August 2008 (2008-08-28) | - |
| OPPOSITION | - Bar-Or Amit, Peter A. J. Calabresi, Douglas Arnold, Clyde Markowitz, Stuart Shafer, Lloyd H. Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J. Fox, Michael Panzara, Neena Sarkar, Sunil Agarwal, Craig H. Smith, "Rituximab in Relapsing-Remitting Multiple Sclerosis: A 72-Week, open-Labelm Phase I trial", American Neurological Association, (20080000), vol. 63, no. 3, doi:10.1002/ana.21363, pages 395 - 400, XP002567455 | |
| OPPOSITION | - Mark C Genovese; Jeffrey L Kaine; Mitchell B Lowenstein; José Del Giudice; Andrew Baldassare; Joy Schechtman; Edward Fudman; Michael Kohen; Sheila Gujrathi; Robert G Trapp; Nadera J Sweiss; Greg Spaniolo; Wolfgang Dummer, "Ocrelizumab, a humanized Anti- CD 20 Monoclonal Antibody in the treatment of patients with rheumatoid arthritis : A phase I/II randomized, blinded, placebo-controlled, dose-ranging study", Arthritis & Rheumatism, (20080901), vol. 58, no. 9, pages 2652 - 2661, XP055190940 | |
| OPPOSITION | - Buttmann M., Rieckmann P., "Treating Multiple Sclerosis with Mono- clonal Antibodies Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial", Expert Review of Neurotherapeutics, (20080000), vol. 8, no. 3, pages 433 - 455, XP009186339 | |
| OPPOSITION | - Pitiot Aubin, Heuzé-Vourc’h Nathalie, Sécher Thomas, "Alternative Routes of Administration for Therapeutic Antibodies—State of the Art", Antibodies, M D P I AG, CH, CH , (20220826), vol. 11, no. 3, doi:10.3390/antib11030056, ISSN 2073-4468, pages 1 - 25, XP093182433 | |
| OTHER | - Van Kempen et al., "Extended dosing of monoclonal antibodies in multiple sclerosis", MULTIPLE SCLEROSIS JOURNAL, (20210101), doi:10.1177/13524585211065711, pages 1 - 9, XP055939590 | |
| OTHER | - Evertsson et al., "Original Research Paper A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis", Multiple Sclerosis Joumal - Experimental, Translational and Clinical, (20201001), doi:10.1177/2055217320964505, pages 1 - 8, XP055939579 | |
| SEARCH | [ ] - HARTUNG HANS-PETER ET AL, "Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.", ANNALS OF NEUROLOGY OCT 2009, (200910), vol. 66, no. 4, ISSN 1531-8249, pages 429 - 432, XP009129053 [ ] * the whole document * | - |
| SEARCH | - HAWKER KS ET AL, "Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, multicenter trial", MULTIPLE SCLEROSIS, SAGE PUBLICATIONS, BASINGSTOKE, GB, (20080826), vol. 14, ISSN 1352-4585, page S299, XP009128819 [Y] 1-24 * the whole document * | - |
| SEARCH | - ROXBURGH R H S R ET AL, "Multiple sclerosis severity score - Using disability and disease duration to rate disease severity", NEUROLOGY, (200504), vol. 64, no. 7, ISSN 0028-3878, pages 1144 - 1151, XP002567456 [A] 1-24 * the whole document * | - |
| SEARCH | - PETEREIT HELA-F ET AL, "EFFECTIVE SUPPRESSION OF CEREBROSPINAL FLUID B CELLS BY RITUXIMAB AND CYCLOPHOSPHAMIDE IN PROGRESSIVE MULTIPLE SCLEROSIS", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, (20051001), vol. 62, no. 10, ISSN 0003-9942, pages 1641 - 1642, XP009085305 [X] 1,16-19 * the whole document * [I] 2-15,20-24 | |
| SEARCH | - MONSON NANCY L ET AL, "EFFECT OF RITUXIMAB ON THE PERIPHERAL BLOOD AND CEREBROSPINAL FLUID B CELLS IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, (20050201), vol. 62, no. 2, ISSN 0003-9942, pages 258 - 264, XP009085313 [X] 1-2,5,10,16,18 * the whole document * [I] 3-4,6-9,11-15,17,19-24 | |
| SEARCH | - MCDONALD W I ET AL, "RECOMMENDED DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS: GUIDELINES FROM THE INTERNATIONAL PANEL ON THE DIAGNOSIS OF MULTIPLE SCLEROSIS", ANNALS OF NEUROLOGY, JOHN WILEY AND SONS, BOSTON, US, (20010701), vol. 50, no. 1, ISSN 0364-5134, pages 121 - 127, XP009053064 [A] 1-24 * the whole document * | |
| SEARCH | - WOLINSKY JERRY S ET AL, "Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial", ANNALS OF NEUROLOGY, (200701), vol. 61, no. 1, ISSN 0364-5134, pages 14 - 24, XP002567459 [A] 1-24 * the whole document * | |
| SEARCH | - BAR-OR AMIT ET AL, "Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial", ANNALS OF NEUROLOGY, (200803), vol. 63, no. 3, ISSN 0364-5134, pages 395 - 400, XP002567455 [A] 1-24 * the whole document * | |
| SEARCH | - HAWKER KATHLEEN ET AL, "Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial", ANNALS OF NEUROLOGY, (20090909), vol. 66, no. 4, ISSN 0364-5134, pages 460 - 471, XP002567460 [PX] 1-24 * the whole document * | |
| SEARCH | - CROSS A H ET AL, "Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 180, no. 1-2, ISSN 0165-5728, (20061101), pages 63 - 70, (20061101), XP025039481 [A] 1-24 * the whole document * | |
| SEARCH | - HAUSER STEPHEN L ET AL, "B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis", NEW ENGLAND JOURNAL OF MEDICINE, (200802), vol. 358, no. 7, ISSN 0028-4793, pages 676 - 688, XP002567454 [A] 1-24 * the whole document * | |
| SEARCH | - WANG RUI ET AL, "Statistics in medicine - Reporting of subgroup analyses in clinical trials", NEW ENGLAND JOURNAL OF MEDICINE, (200711), vol. 357, no. 21, ISSN 0028-4793, pages 2189 - 2194, XP002567458 [A] 1-24 * the whole document * | |
| SEARCH | - GROUIN J -M ET AL, "Subgroup analyses in randomized clinical trials: Statistical and regulatory issues", JOURNAL OF BIOPHARMACEUTICAL STATISTICS 2005 US, (2005), vol. 15, no. 5, pages 869 - 882, XP009129300 [A] 1-24 * the whole document * | |
| SEARCH | - HAWKER K, "B-cell-targeted treatment for multiple sclerosis: Mechanism of action and clinical data", CURRENT OPINION IN NEUROLOGY, RAPID SCIENCE PUBLISHERS, LONDON, GB, (20080401), vol. 21, no. SUPPL 1, ISSN 1350-7540, pages S19 - S25, XP008102094 [Y] 1-24 * the whole document * | |
